VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

23 A EGIS C APITAL C ORP. Fig. 12. Historical financial highlights Source: VistaGen 6/30 Cash and equivalents $1.55mm EverInsight Therapeutics PH94B license payment $5.00mm 8/10 underwritten public offering $14.29mm FY:20 net cash used in operating activities -$15.80mm FY:19 net cash used in operating activities -$14.50mm Operating cash use Balance sheet highlights VistaGen Therapeutics, Inc. October 8, 2020